{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T02:52:10Z","timestamp":1764557530938},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1038\/s41409-020-0801-0","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T17:05:12Z","timestamp":1580403912000},"page":"1410-1420","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Monitoring minimal residual\/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia"],"prefix":"10.1038","volume":"55","author":[{"given":"Klaus","family":"Wethmar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja","family":"Matern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"E\u00dfeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linus","family":"Angenendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Stelmach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Call","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn C.","family":"Albring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Groth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"801_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Socie G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139\u201349. https:\/\/doi.org\/10.3324\/haematol.2016.145631","journal-title":"Haematologica"},{"key":"801_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","volume":"101","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia. Haematologica. 2016;101:1524\u201333. https:\/\/doi.org\/10.3324\/haematol.2016.144311","journal-title":"Haematologica"},{"key":"801_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277.","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl J Med. 2016;375:740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N. Engl J Med"},{"key":"801_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N. Engl J Med. 2017;376:836\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N. Engl J Med"},{"key":"801_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","volume":"107","author":"M Br\u00fcggemann","year":"2006","unstructured":"Br\u00fcggemann M, Raff T, Flohr T, G\u00f6kbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116\u201323. https:\/\/doi.org\/10.1182\/blood-2005-07-2708","journal-title":"Blood"},{"key":"801_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbmt.2008.11.009","volume":"15","author":"MA Pulsipher","year":"2009","unstructured":"Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease\/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant. 2009;15:62\u201371. https:\/\/doi.org\/10.1016\/j.bbmt.2008.11.009","journal-title":"Biol Blood Marrow Transplant"},{"key":"801_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjh.12358","volume":"162","author":"D Campana","year":"2013","unstructured":"Campana D, Leung W. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol. 2013;162:147\u201361. https:\/\/doi.org\/10.1111\/bjh.12358","journal-title":"Br J Haematol"},{"key":"801_CR8","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522\u201331. https:\/\/doi.org\/10.1182\/blood-2017-08-798322","journal-title":"Blood"},{"key":"801_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/leu.2009.268","volume":"24","author":"M Br\u00fcggemann","year":"2010","unstructured":"Br\u00fcggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24:521\u201335. https:\/\/doi.org\/10.1038\/leu.2009.268","journal-title":"Leukemia"},{"key":"801_CR10","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868\u201376. https:\/\/doi.org\/10.1182\/blood-2011-09-377713","journal-title":"Blood"},{"key":"801_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/sj.leu.2401953","volume":"15","author":"C Thiede","year":"2001","unstructured":"Thiede C, Bornh\u00e4user M, Oelschlagel U, Brendel C, Leo R, Daxberger H, et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia. 2001;15:293\u2013302.","journal-title":"Leukemia"},{"key":"801_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.bmt.1704715","volume":"35","author":"P Bader","year":"2005","unstructured":"Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone marrow Transplant. 2005;35:107\u201319. https:\/\/doi.org\/10.1038\/sj.bmt.1704715","journal-title":"Bone marrow Transplant"},{"key":"801_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00007890-198703000-00016","volume":"43","author":"PY Yam","year":"1987","unstructured":"Yam PY, Petz LD, Knowlton RG, Wallace RB, Stock AD, de Lange G, et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation. 1987;43:399\u2013407.","journal-title":"Transplantation"},{"key":"801_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.bmt.1701119","volume":"21","author":"P Bader","year":"1998","unstructured":"Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R, et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone marrow Transplant. 1998;21:487\u201395. https:\/\/doi.org\/10.1038\/sj.bmt.1701119","journal-title":"Bone marrow Transplant"},{"key":"801_CR15","first-page":"801","volume":"88","author":"M Barrios","year":"2003","unstructured":"Barrios M, Jimenez-Velasco A, Roman-Gomez J, Madrigal ME, Castillejo JA, Torres A, et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica. 2003;88:801\u201310.","journal-title":"Haematologica"},{"key":"801_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/sj.bmt.1702504","volume":"26","author":"SJ Choi","year":"2000","unstructured":"Choi SJ, Lee KH, Lee JH, Kim S, Chung HJ, Lee JS, et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone marrow Transplant. 2000;26:327\u201332. https:\/\/doi.org\/10.1038\/sj.bmt.1702504","journal-title":"Bone marrow Transplant"},{"key":"801_CR17","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.bbmt.2014.05.026","volume":"20","author":"TH Terwey","year":"2014","unstructured":"Terwey TH, Hemmati PG, Nagy M, Pfeifer H, G\u00f6kbuget N, Br\u00fcggemann M, et al. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2014;20:1522\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.026","journal-title":"Biol Blood Marrow Transplant"},{"key":"801_CR18","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/sj.leu.2403507","volume":"18","author":"C Scheffold","year":"2004","unstructured":"Scheffold C, Kroeger M, Zuehlsdorf M, Tchinda J, Silling G, Bisping G, et al. Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis. Leukemia. 2004;18:2048\u201350. https:\/\/doi.org\/10.1038\/sj.leu.2403507","journal-title":"Leukemia"},{"key":"801_CR19","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/bmt.2013.2","volume":"48","author":"F Rosenow","year":"2013","unstructured":"Rosenow F, Berkemeier A, Krug U, M\u00fcller-Tidow C, Gerss J, Silling G, et al. CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant. 2013;48:1070\u20136. https:\/\/doi.org\/10.1038\/bmt.2013.2","journal-title":"Bone Marrow Transplant"},{"key":"801_CR20","doi-asserted-by":"publisher","unstructured":"Zeiser R, Spyridonidis A, W\u00e4sch R, Ihorst G, Gr\u00fcllich C, Bertz H et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2005;19:814\u201321. https:\/\/doi.org\/10.1038\/sj.leu.2403719","DOI":"10.1038\/sj.leu.2403719"},{"key":"801_CR21","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3324\/haematol.2009.007765","volume":"94","author":"M Bornh\u00e4user","year":"2009","unstructured":"Bornh\u00e4user M, Oelschlaegel U, Platzbecker U, Bug G, Lutterbeck K, Kiehl MG, et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica. 2009;94:1613\u20137. https:\/\/doi.org\/10.3324\/haematol.2009.007765","journal-title":"Haematologica"},{"key":"801_CR22","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/sj.leu.2402311","volume":"15","author":"J Mattsson","year":"2001","unstructured":"Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia. 2001;15:1976\u201385.","journal-title":"Leukemia"},{"key":"801_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-1-4614-9437-9_14","volume":"1109","author":"S Preuner","year":"2014","unstructured":"Preuner S, Lion T. Post-transplant monitoring of chimerism by lineage-specific analysis. Methods Mol Biol. 2014;1109:271\u201391. https:\/\/doi.org\/10.1007\/978-1-4614-9437-9_14","journal-title":"Methods Mol Biol"},{"key":"801_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3324\/haematol.2015.135137","volume":"101","author":"S Preuner","year":"2016","unstructured":"Preuner S, Peters C, P\u00f6tschger U, Daxberger H, Fritsch G, Geyeregger R, et al. Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. Haematologica. 2016;101:741\u20136. https:\/\/doi.org\/10.3324\/haematol.2015.135137","journal-title":"Haematologica"},{"key":"801_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/bmt.2010.179","volume":"46","author":"M Tobiasson","year":"2011","unstructured":"Tobiasson M, Olsson R, Hellstr\u00f6m-Lindberg E, Mattsson J. Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant. 2011;46:719\u201326. https:\/\/doi.org\/10.1038\/bmt.2010.179","journal-title":"Bone Marrow Transplant"},{"key":"801_CR26","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.bbmt.2010.06.005","volume":"16","author":"D Sairafi","year":"2010","unstructured":"Sairafi D, Remberger M, Uhlin M, Ljungman P, Ringd\u00e9n O, Mattsson J. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2010;16:1728\u201337. https:\/\/doi.org\/10.1016\/j.bbmt.2010.06.005","journal-title":"Biol Blood Marrow Transplant"},{"key":"801_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-59745-223-6_14","volume":"134","author":"T Lion","year":"2007","unstructured":"Lion T. Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med. 2007;134:197\u2013216.","journal-title":"Methods Mol Med"},{"key":"801_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","volume":"24","author":"N G\u00f6kbuget","year":"2019","unstructured":"G\u00f6kbuget N, Dombret H, Giebel S, Br\u00fcggemann M, Doubek M, Foa R, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019;24:337\u201348. https:\/\/doi.org\/10.1080\/16078454.2019.1567654","journal-title":"Hematology"},{"key":"801_CR29","doi-asserted-by":"publisher","unstructured":"Bassan R, Br\u00fcggemann M, Radcliffe H-S, Hartfield E, Kreuzbauer G, Wetten S. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019. https:\/\/doi.org\/10.3324\/haematol.2018.201053","DOI":"10.3324\/haematol.2018.201053"},{"key":"801_CR30","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580 https:\/\/doi.org\/10.1001\/jamaoncol.2017.0580","journal-title":"JAMA Oncol"},{"key":"801_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4670-5","volume":"18","author":"Z Shen","year":"2018","unstructured":"Shen Z, Gu X, Mao W, Yin L, Yang L, Zhang Z, et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18:755 https:\/\/doi.org\/10.1186\/s12885-018-4670-5","journal-title":"BMC Cancer"},{"key":"801_CR32","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1200\/jco.2004.05.198","volume":"22","author":"P Bader","year":"2004","unstructured":"Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol. 2004;22:1696\u2013705. https:\/\/doi.org\/10.1200\/jco.2004.05.198","journal-title":"J Clin Oncol"},{"key":"801_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/jco.2014.58.4631","volume":"33","author":"P Bader","year":"2015","unstructured":"Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015;33:1275\u201384. https:\/\/doi.org\/10.1200\/jco.2014.58.4631. e-pub ahead of print 2015\/01\/22","journal-title":"J Clin Oncol"},{"key":"801_CR34","first-page":"24","volume":"1","author":"J Radich","year":"1995","unstructured":"Radich J, Ladne P, Gooley T. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT. Biol Blood Marrow Transplant. 1995;1:24\u201331.","journal-title":"Biol Blood Marrow Transplant"},{"key":"801_CR35","doi-asserted-by":"publisher","unstructured":"Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. 2007;92:612\u20138. https:\/\/doi.org\/10.3324\/haematol.10965","DOI":"10.3324\/haematol.10965"},{"key":"801_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/bmt.2008.155","volume":"42","author":"K Doney","year":"2008","unstructured":"Doney K, Loken M, Bryant E, Smith A, Appelbaum F. Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL. Bone Marrow Transplant. 2008;42:271\u20134. https:\/\/doi.org\/10.1038\/bmt.2008.155.","journal-title":"Bone Marrow Transplant"},{"key":"801_CR37","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311. https:\/\/doi.org\/10.1038\/sj.leu.2404586","journal-title":"Leukemia"},{"key":"801_CR38","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program. Leukemia. 2003;17:2318\u201357. https:\/\/doi.org\/10.1038\/sj.leu.2403135","journal-title":"Leukemia"},{"key":"801_CR39","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program. Leukemia. 2003;17:2474\u201386. https:\/\/doi.org\/10.1038\/sj.leu.2403136","journal-title":"Leukemia"},{"key":"801_CR40","doi-asserted-by":"publisher","unstructured":"Pochon C, Oger E, Michel G, Dalle J-H, Salmon A, Nelken B et al. Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react. Br J Haematol. 2015;169:249\u201361. https:\/\/doi.org\/10.1111\/bjh.13272","DOI":"10.1111\/bjh.13272"},{"key":"801_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bmt.2008.339","volume":"43","author":"B Horn","year":"2009","unstructured":"Horn B, Soni S, Khan S, Petrovic A, Breslin N, Cowan M, et al. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant. 2009;43:469\u201376. https:\/\/doi.org\/10.1038\/bmt.2008.339","journal-title":"Bone Marrow Transplant"},{"key":"801_CR42","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.bmt.1703859","volume":"31","author":"G Massenkeil","year":"2003","unstructured":"Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G, et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant. 2003;31:339\u201345. https:\/\/doi.org\/10.1038\/sj.bmt.1703859","journal-title":"Bone Marrow Transplant"},{"key":"801_CR43","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2141.2002.3311a.x","volume":"116","author":"J Sanchez","year":"2002","unstructured":"Sanchez J, Serrano J, Gomez P, Martinez F, Martin C, Madero L, et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol. 2002;116:686\u201394.","journal-title":"Br J Haematol"},{"key":"801_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2016.10.006","volume":"23","author":"E Rettinger","year":"2017","unstructured":"Rettinger E, Merker M, Salzmann-Manrique E, Kreyenberg H, Krenn T, D\u00fcrken M, et al. Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2017;23:87\u201395. https:\/\/doi.org\/10.1016\/j.bbmt.2016.10.006","journal-title":"Biol Blood Marrow Transplant"},{"key":"801_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.bmt.1704321","volume":"33","author":"E Gorczynska","year":"2004","unstructured":"Gorczynska E, Turkiewicz D, Toporski J, Kalwak K, Rybka B, Ryczan R, et al. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children. Bone Marrow Transplant. 2004;33:211\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1704321","journal-title":"Bone Marrow Transplant"},{"key":"801_CR46","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/leu.2012.352","volume":"27","author":"H Pfeifer","year":"2013","unstructured":"Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornh\u00e4user M, Stadler M, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27:1254\u201362. https:\/\/doi.org\/10.1038\/leu.2012.352","journal-title":"Leukemia"},{"key":"801_CR47","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","volume":"125","author":"N Dh\u00e9din","year":"2015","unstructured":"Dh\u00e9din N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486\u201396. https:\/\/doi.org\/10.1182\/blood-2014-09-599894","journal-title":"Blood"},{"key":"801_CR48","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1182\/blood.V99.7.2315","volume":"99","author":"T Szczepan\u0301ski","year":"2002","unstructured":"Szczepan\u0301ski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJM. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B\u2013ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood. 2002;99:2315\u201323. https:\/\/doi.org\/10.1182\/blood.V99.7.2315","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0801-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:42Z","timestamp":1684617462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0801-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0801-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"30 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}